Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reduc

Up-front treatment with navitoclax plus ruxolitinib significantly reduced spleen volume by 35% or more at week 24 vs ruxolitinib plus placebo in patients with myelofibrosis; however, a significant difference was not observed in total symptom score v. 4.0 between the arms, according to data from the phase 3 TRANSFORM-1 study.

Related Keywords

Texas , United States , Houston , Naveen Pemmaraju , Department Of Leukemia , University Of Texas Md Anderson Cancer Center , Cancer Center , Navitoclax , Navitoclax Plus Ruxolotinib , Myelofibrosis , Cash , Ash Annual Meeting , Transform 1 Study , D , Md Anderson ,